Anticholinergic Burden - Treatment Optimization

Completed

• Conditions: Anticholinergics; Cognitive Function

• Registration Number: NCT03208569
• Lead Sponsor: Region Skane

Brief Summary

There is increasing evidence that medications with anticholinergic effects may adversely affect cognitive function. Older adults are particularly sensitive to anticholinergic effects because of changes in pharmacokinetics and pharmacodynamics. The cumulative effect of taking one or more medicines with anticholinergic properties is referred to as anticholinergic burden. To estimate the anticholinergic burden, Boustani et al. published the Anticholinergic Cognitive Burden scale (2008). The objective of this study is to measure the association between the use of medications with anticholinergic properties (identified by the ACB scale) and cognitive performance. Anticholinergic use and cognitive performance will be measured at baseline and 6-months follow-up.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-06-27
• Study First Submitted QC: 2017-07-03
• Study First Posted: 2017-07-05
• Study Start: 2017-09-01
• Primary Completion: 2021-09-30
• Study Completion: 2021-09-30
• Status Verified: 2021-10
• Last Update Submitted: 2023-11-06
• Last Update Posted: 2023-11-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 665

Inclusion Criteria

• 50 years and older

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive function	6 months	Cognitive function, measured by the Mini-Mental State Examination (MMSE)

Secondary Outcome Measures

Name	Time	Method
Cognitive function	6 months	Cognitive function, measured by A Quick Test of cognitive speed (AQT)
Anticholinergic burden	6 months	Anticholinergic burden, determined according to the Anticholinergic Burden scale

Trial Locations

Locations (1)

Specialistminnesmottagningen; 🇸🇪 Ängelholm, Sweden